Advertisement

Topics

GlaxoSmithKline's Pain in China is AstraZeneca's Gain

19:00 EST 8 Nov 2017 | BioSpace

China revenue in Q3increased by 12 percent at AstraZeneca and the country now accounts for 15 percent of its global product sales.

Original Article: GlaxoSmithKline's Pain in China is AstraZeneca's Gain

NEXT ARTICLE

More From BioPortfolio on "GlaxoSmithKline's Pain in China is AstraZeneca's Gain"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...